Takashi Akiyoshi

The Cancer Institute Hospital
Country flagJapan

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (18)

Purpose: The role of ctDNA in total neoadjuvant therapy (TNT) and nonoperative management (NOM) for locally advanced rectal cancer (LARC) remains unclear. We evaluated the association of ctDNA with clinical outcomes, including treatment response, local regrowth, and distant recurrence in patients undergoing TNT and NOM. Experimental Design: This biomarker companion analysis of the NOMINATE trial, a prospective, multicenter, randomized phase II study, enrolled 64 patients with T3 to T4NanyM0 LARC between March 2021 and July 2023. Plasma samples ( n = 412) were collected at multiple time points: pretreatment (T0), interim evaluations (T1 and T2), final re-staging (T3), and after surgery or after NOM (T4 and beyond). ctDNA was monitored using a tumor-informed multiplex polymerase chain reaction–next generation sequencing assay (Signatera). The association between ctDNA status and clinical outcomes was analyzed. Results: Baseline ctDNA detection was 98.4%, which decreased to 32% at T1, 15% at T2, 30% at T3, and 5% at T4. Among 25 patients achieving clinical complete response (cCR) or near cCR with NOM, ctDNA clearance was 100% at T2 to T4, whereas 39 non-cCR patients showed lower clearance rates (75% at T2 and 51% at T3). ctDNA at T3 had 100% specificity and positive predictive value for pathologic residual disease and was associated with shorter disease-free survival (HR = 6.7, P = 0.005). Local regrowth occurred in five NOM patients, with ctDNA detected in two during surveillance. Conclusions: This study highlights the potential of ctDNA as a predictive and prognostic biomarker in patients with LARC undergoing TNT and subsequently managed by NOM. However, the modest sensitivity of ctDNA highlights the need for technological improvements. See related commentary by Bent et al., p. 5117

Year:

2025

Lateral lymph node dissection (LLND) is recognized as an effective treatment for reducing local recurrence in patients with locally advanced lower rectal cancer. However, the lack of standardization in techniques and anatomical landmarks remains a concern, as it may complicate the assessment of treatment efficacy. To address this, the Japan Society of Gastroenterological Surgery (JSGS) held a consensus meeting during the 77th General Meeting of the JSGS to standardize LLND techniques. In this meeting, essential anatomical landmarks for LLND were confirmed. The primary regions targeted for dissection include lymph nodes in the obturator region (designated as station 283) and those in the internal iliac region (designated as station 263). The medial boundary of LLND is defined by the uretero‐hypogastric fascia, whereas the vesico‐hypogastric fascia constitutes the central plane of dissection and serves as the medial boundary of station 283. Indicators of successful LLND completion include exposure of the sciatic nerve (lumbosacral trunk) at the bottom of the dissection, as well as exposure of the inferior vesical vessels, internal pudendal artery, and coccygeus muscle, confirming the thoroughness of the caudal part of the dissection. The consensus reached in this meeting, along with findings from several published reports cited in this report, is expected to contribute to the standardization of LLND quality.

Year:

2025

Aims This study aimed to reevaluate the prognostic significance of the number of harvested lymph nodes (LNs) and its predictive value for adjuvant chemotherapy (ACT) in stage II colon cancer (CC), considering tumor sidedness. Methods Pathological stage II CC patients who underwent curative surgery with Japanese D3 lymphadenectomy were assessed using a Japanese database. The optimal cutoff for harvested LNs was evaluated by analyzing all cutoff values ( n = 4–40). A Cox proportional hazards model was used to investigate the impact of the number of harvested LNs on overall survival (OS), and the impact of ACT on OS in subgroups based on the cutoff of 12 LNs and the calculated optimal cutoffs. Results A total of 3526 (left/right; 2684/842) pathological stage II CC patients were identified. A cutoff of 12LNs was identified as a prognostic factor for OS (HR 1.45; [95% CI: 1.15–1.82]). However, a stronger prognostic impact was observed with a cutoff of seven (HR 2.04; [1.44–2.88]). Subgroup analysis based on sidedness revealed variations in the optimal cutoff (7 for left‐sided [HR 2.25; (1.54–3.280)]) and 10 for right‐sided (HR 1.82; [1.02–3.26]). The survival benefit of ACT was not observed across all cutoffs. Conclusion Although cutoffs other than 12 LNs demonstrated stronger prognostic value in certain subgroups, harvesting ≥ 12 LNs remained a consistent prognostic factor across sidedness. The number of harvested LNs may not be a useful predictive factor of ACT in stage II CC.

Year:

2025

Total neoadjuvant therapy (TNT) improves oncological outcomes in locally advanced rectal cancer (LARC); however, treatment-induced lymphopenia remains a concern. We analyzed 74 patients undergoing three TNT regimens: long-course chemoradiotherapy with consolidation chemotherapy (LCCRT–CNCT), short-course radiotherapy with CNCT (SCRT–CNCT), and induction chemotherapy with LCCRT (INCT–LCCRT). Severe radiation-induced lymphopenia (RIL, Grade ≥ 3) occurred in 48%, 24%, and 54%, respectively (P = 0.126). In the LCCRT–CNCT group, large bowel irradiation (V35 Gy > 46 cc) was significantly associated with severe RIL in univariable analysis but not in multivariable models (P = 0.227), and in an exploratory combined analysis of LCCRT–CNCT and INCT–LCCRT, this showed a trend (P = 0.093). Pre-TNT absolute lymphocyte count (ALC) was an independent predictor of RIL. Small bowel irradiation (V15 Gy > 104 cc) predicted severe lymphopenia during chemotherapy in the univariable analysis; but multivariable analysis suggested pre-TNT ALC as the main factor, showing a trend toward significance (P = 0.051). In the SCRT–CNCT group, pre-TNT ALC was the only significant factor for severe lymphopenia in both the RT and chemotherapy phases in univariable analysis. Severe RIL significantly prolonged lymphocyte recovery time (median, 283 vs. 76 days, P < 0.001), whereas immune recovery did not differ according to the TNT regimen. The median ALC at the last follow-up was 86% of the baseline value, indicating incomplete recovery. While pre-TNT ALC correlated with lymphopenia risk, minimizing bowel irradiation may help mitigate treatment-induced immunosuppression. Prospective studies are required to validate these findings.

Year:

2025

Limited data are available on the impact of RAS mutations in patients with locally advanced rectal cancer treated with total neoadjuvant therapy (TNT). This retrospective study aimed to evaluate the effect of RAS mutations on treatment efficacy in 290 patients with locally advanced rectal cancer without distant metastasis, treated between 2015 and 2021 with neoadjuvant long‐course chemoradiotherapy (CRT) with or without neoadjuvant systemic chemotherapy. RAS mutations were analyzed using pretreatment biopsy specimens. Associations between mutations and clinical outcomes were assessed separately in 146 patients who underwent conventional CRT and 144 patients who underwent TNT. RAS mutations were identified in 42.5% and 51.4% of the CRT and TNT groups, respectively. No significant association was observed in either group between RAS mutation and complete response (CR, defined as pathological CR or sustained clinical CR after non‐operative management). However, in the multivariable analysis, RAS mutations were significantly associated with a high neoadjuvant rectal score and worse recurrence‐free survival in the CRT group. Yet, no such associations were observed in the TNT group, suggesting that TNT may mitigate the adverse effects of RAS mutations. Although further prospective, multicenter studies are required, our data suggest that RAS mutations may predict poor responses and higher recurrence risk among patients with locally advanced rectal cancer, and that TNT may be the better treatment option for these patients.

Year:

2025

Aims To determine the optimal extent of lymph node dissection for non‐metastatic colon cancer by tumor location based on the therapeutic value index (TVI) for each lymph node station. Methods Consecutive patients with surgical stage I–III colon or rectosigmoid cancer in the Japanese Society for Cancer of the Colon and Rectum database who underwent curative resection between January 2003 and December 2014 were analyzed. The TVI was defined as the incidence of lymph node metastasis multiplied by 5‐year overall survival and calculated for each nodal station stratified by tumor location. Results A total of 33 231 patients were eligible for analysis. In cecal cancer, the TVI was 2.086 for nodal station #203, but only 0.000 for #213. In ascending colon cancer, the TVI was 1.080 for #203 and 0.644 for #213, but only 0.178 for #223. In transverse colon cancer, the TVI was 1.942 for #223, but only 0.066 for #213 and 0.159 for #203. In descending colon cancer, the TVI was 0.215 for #253. The TVI was 1.172 for #253 in sigmoid colon cancer and 1.155 for #253 in rectosigmoid cancer. Conclusion Considering that a previous systematic review reported TVIs in the range of 0.295–0.576 for the para‐aortic lymph nodes in patients with colorectal cancer, dissection of the main lymph nodes along the feeding artery has a therapeutic value in non‐metastatic colon cancers. Meanwhile, the significance of #253 dissection for descending colon cancer requires further discussion.

Year:

2025

BACKGROUND: Desmoplastic reaction is recognized as a prognostic factor in colorectal cancer. However, its significance in locally advanced rectal cancer after neoadjuvant chemoradiotherapy remains underexplored. OBJECTIVE: To assess the prognostic value of desmoplastic reaction in specimens from patients with advanced rectal cancer after chemoradiotherapy. DESIGN: This was a retrospective study. SETTINGS: This study was conducted at a single comprehensive cancer center. PATIENTS: The study included 255 patients with advanced rectal cancer who underwent fluoropyrimidine-based chemoradiotherapy followed by total mesorectal excision from 2005 to 2014. Desmoplastic reaction was classified into mature, intermediate, and immature categories based on histological analysis. MAIN OUTCOME MEASURES: The primary outcomes were recurrence-free survival and overall survival. RESULTS: Desmoplastic reaction was classified as mature (69.0%), intermediate (5.5%), or immature (25.5%). The mature group had a higher percentage of good responders (34.1%) compared with the intermediate (0%) and immature (4.6%) groups ( p < 0.0001). The mature group correlated with better outcomes, with a higher 5-year recurrence-free survival (85.4%) and overall survival (93.0%) as compared with intermediate (45.1% and 76.2%, respectively) and immature (65.8% and 88.8%, respectively) groups. In the multivariable analysis, intermediate/immature desmoplastic reaction was significantly associated with poorer recurrence-free survival ( p = 0.03). Among poor responders, intermediate/immature desmoplastic reaction was associated with poorer recurrence-free survival ( p = 0.03). Adjuvant chemotherapy did not significantly improve the 5-year recurrence-free survival rate for the mature group (adjuvant chemotherapy vs no chemotherapy, 86.4% vs 84.8%; p = 0.64), with worse trends observed in the intermediate/immature combined group (55.9% vs 69.4%, respectively, p = 0.27). LIMITATIONS: The limitations include the subjective nature of the desmoplastic reaction assessment and the retrospective design of the study. CONCLUSIONS: Desmoplastic reaction in surgical specimens after chemoradiotherapy is associated with responses to chemoradiotherapy and serves as a significant prognostic factor in advanced rectal cancer, particularly for those responding poorly to chemoradiotherapy. See Video Abstract . IMPORTANCIA PRONÓSTICA DE LA REACCIÓN DESMOPLÁSICA TRAS LA QUIMIORRADIOTERAPIA NEOADYUVANTE EN EL CÁNCER RECTAL AVANZADO ANTECEDENTES: La reacción desmoplásica se reconoce como un factor pronóstico en el cáncer colorrectal. Sin embargo, su importancia en el cáncer rectal localmente avanzado después de la quimiorradioterapia neoadyuvante sigue sin explorarse. OBJETIVO: Evaluar el valor pronóstico de la reacción desmoplásica en muestras de pacientes con cáncer rectal avanzado después de la quimiorradioterapia. DISEÑO: Este es un estudio retrospectivo. ESCENARIO: Este estudio se llevó a cabo en un solo centro oncológico integral. PACIENTES: El estudio incluyó a 255 pacientes con cáncer rectal avanzado que se sometieron a quimiorradioterapia basada en fluoropirimidina seguida de una escisión mesorrectal total entre 2005 y 2014. La reacción desmoplásica se clasificó en categorías madura, intermedia e inmadura según el análisis histológico. RESULTADOS PRINCIPALES: Los resultados primarios fueron la supervivencia sin recurrencia y la supervivencia general. RESULTADOS: La reacción desmoplásica se clasificó como madura (69,0%), intermedia (5,5%) o inmadura (25,5%). El grupo maduro tuvo un mayor porcentaje de buenos respondedores (34,1%) en comparación con los grupos intermedio (0%) e inmaduro (4,6%) (p < 0,0001). El grupo maduro se correlacionó con mejores resultados, con una mayor supervivencia libre de recurrencia a 5 años (85,4%) y supervivencia general (93,0%) en comparación con los grupos intermedio (45,1% y 76,2%, respectivamente) e inmaduro (65,8% y 88,8%, respectivamente). En el análisis

Year:

2024

BACKGROUND: There is a lack of consensus regarding treating involved lateral pelvic lymph nodes in rectal cancer. OBJECTIVE: This study aimed to evaluate the clinical and MRI-based factors associated with pathological lateral pelvic lymph node metastasis in patients undergoing total neoadjuvant therapy and lateral pelvic lymph node dissection. DESIGN: This is a retrospective study. SETTINGS: This study was conducted at a single comprehensive cancer center. PATIENTS: A total of 107 patients with advanced low rectal cancer with pretreatment enlarged lateral pelvic lymph nodes (≥7 mm in long axis) undergoing total neoadjuvant therapy with long-course chemoradiotherapy, followed by total mesorectal excision and lateral pelvic lymph node dissection, were enrolled. MAIN OUTCOME MEASURES: Pathological lateral pelvic lymph node metastasis and survival. RESULTS: Among 107 patients, short-axis lateral node diameter at baseline was <7 mm in 48 patients and ≥7 mm in 59 patients. The ≥7 mm group showed significantly higher rates of pathological lateral pelvic lymph node metastasis (44.1% vs 2.1%; p < 0.0001). In this group, pathological lateral pelvic lymph node metastasis was independently associated with pretreatment malignant features and posttreatment short-axis diameter ≥4 mm. Five-year relapse-free survival was significantly lower in patients with posttreatment lateral node diameter ≥4 mm than those with <4 mm (71.1% vs 86.2%, p = 0.0364). Patients with pathological lateral pelvic lymph node metastasis had significantly lower overall survival, relapse-free survival, and local recurrence-free survival rates. LIMITATIONS: Selection bias exists in a retrospective analysis. CONCLUSIONS: Pathological lateral pelvic lymph node metastasis is rare in patients with pretreatment short-axis diameter <7 mm. In patients with pretreatment short-axis diameter ≥7 mm, pretreatment malignant features and posttreatment short-axis diameter are both associated with pathological lateral pelvic lymph node metastasis. These factors should be considered when deciding whether to proceed with lateral pelvic lymph node dissection after total neoadjuvant therapy. See Video Abstract . CARACTERÍSTICAS DE LOS GANGLIOS LINFÁTICOS PÉLVICOS LATERALES ASOCIADOS CON AFECTACIÓN PATOLÓGICA DESPUÉS DE LA TERAPIA NEOADYUVANTE TOTAL EN PACIENTES SOMETIDOS A DISECCIÓN LATERAL DE GANGLIOS LINFÁTICOS PÉLVICOS ANTECEDENTES: No existe consenso sobre el tratamiento de los ganglios linfáticos pélvicos laterales afectados en el cáncer rectal. OBJETIVO: Este estudio tuvo como objetivo evaluar los factores clínicos y basados en imágenes de resonancia magnética asociados con la metástasis patológica de los ganglios linfáticos pélvicos laterales en pacientes sometidos a terapia neoadyuvante total y disección lateral de ganglios linfáticos pélvicos. DISEO: Este es un estudio retrospectivo. EORNO CLINICO: Este estudio se llevó a cabo en un solo centro oncológico integral. PACIENTES: Se inscribieron 107 pacientes con cáncer rectal bajo avanzado con ganglios linfáticos pélvicos laterales agrandados antes del tratamiento (≥7 mm en el eje largo) sometidos a terapia neoadyuvante total con quimiorradioterapia de larga duración, seguida de escisión mesorrectal total y disección de ganglios linfáticos pélvicos laterales. PRINCIPALES MEDIDAS DE RESULTADOS: Metástasis patológica de ganglios linfáticos pélvicos laterales y supervivencia. RESULTADOS: Entre 107 pacientes, 48 tenían un diámetro ganglionar lateral en el eje corto <7 mm al inicio, mientras que 59 tenían ≥7 mm. El grupo de ≥7 mm mostró tasas significativamente más altas de metástasis patológica de los ganglios linfáticos pélvicos laterales (44,1% vs 2,1%; p < 0,0001). En este grupo, la metástasis patológica de los ganglios linfáticos pélvicos laterales se asoció de forma independiente con características malignas previas al tratamiento y un diámetro ganglionar lateral posterior al tratamiento ≥4 mm. La supervivencia sin recidiva a los cin

Year:

2024

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Collaborators (3)

Kohei Shigeta

Assistant Professor

Keio University School of Medicine

JAPAN
View details

Itaru Endo

-

JAPAN
View details

Minetta Liu

Research Collaborator, Professor

Mayo Clinic

UNITED STATES
View details